Compassionate Use Pathways for Tigilanol Tiglate: How Patients May Access EBC-46 Before Full Approval
Compassionate use and expanded access programmes could allow terminal patients to receive tigilanol tiglate before regulatory approval is finalised.
When Regulatory Timelines Outpace Patient Need
For patients with advanced, treatment-resistant cancers, the years-long regulatory pipeline can feel like a sentence in itself. Compassionate use — sometimes called expanded access — exists precisely for this gap: a mechanism by which seriously ill patients can receive investigational drugs outside of clinical trials when no comparable alternatives exist.[1]
Tigilanol tiglate, the lead pharmaceutical compound derived from the seeds of Fontainea picrosperma (the Blushwood tree), is currently progressing through human clinical trials for solid tumours.[2] Its remarkable track record in veterinary oncology — where it received FDA approval as Stelfonta for canine mast cell tumours in 2020[3] — has intensified interest in accelerating human access.
What Is Compassionate Use?
Compassionate use programmes, formally known as expanded access in the United States, allow patients with serious or life-threatening conditions to use investigational drugs that have not yet received marketing authorisation. The FDA's expanded access framework requires that the potential benefit justifies the potential risks, that no satisfactory alternatives exist, and that providing the drug will not interfere with ongoing clinical trials.[4]
In Europe, the EMA operates a similar framework under Article 83 of Regulation (EC) No 726/2004, which permits compassionate use for groups of patients with chronically or seriously debilitating diseases who cannot be treated satisfactorily by an authorised medicinal product.[5]
The Case for Tigilanol Tiglate Compassionate Access
Several features of tigilanol tiglate make it a strong candidate for compassionate use consideration. First, its mechanism of action — direct intratumoral injection triggering localised tumour destruction via PKC activation and vascular disruption[6] — means the drug acts locally with limited systemic exposure, potentially reducing the risk profile compared to systemic chemotherapies.
Second, the extensive veterinary dataset from Stelfonta provides a substantial body of safety and efficacy evidence. More than 100 dogs were treated in the pivotal registration trials, with complete response rates exceeding 75% for mast cell tumours.[7]
Third, QBiotics Group, the developer of tigilanol tiglate, has already progressed to human Phase I and Phase II trials, establishing initial safety data in human cancer patients.[8]
Regulatory Precedents and Parallel Pathways
The transition from veterinary approval to human expanded access is not without precedent. The FDA has historically recognised that robust animal data, combined with early human safety signals, can justify compassionate access — particularly for drugs with novel mechanisms addressing unmet needs.
QBiotics has also pursued additional regulatory accelerators. Orphan Drug Designation, which provides incentives for drugs targeting rare diseases affecting fewer than 200,000 patients in the US, could apply to specific rare tumour types for which tigilanol tiglate shows promise.[9]
The EMA's PRIME (PRIority MEdicines) scheme, designed to enhance support for medicines that may offer a major therapeutic advantage over existing treatments, represents another pathway that could accelerate European access to tigilanol tiglate.
What This Means for Patients
While compassionate use is not a guarantee and requires case-by-case evaluation, the existence of these regulatory frameworks means that patients with advanced solid tumours who have exhausted standard treatment options may eventually have a formal pathway to request access to tigilanol tiglate. The combination of a novel, locally-acting mechanism, strong veterinary evidence, and ongoing human trials positions EBC-46 as a compelling candidate for such programmes.
As clinical data from human trials continues to mature, the probability of expanded access increases. For patients and oncologists watching the tigilanol tiglate development programme, understanding these regulatory pathways is essential for informed advocacy and planning.
References
- FDA — Designating an Orphan Product: Drugs and Biological Products View source ↗
- ClinicalTrials.gov — Tigilanol tiglate search results View source ↗
- FDA — Stelfonta approval announcement View source ↗
- FDA — Expanded access regulatory framework View source ↗
- EMA — Stelfonta EPAR View source ↗
- Boyle et al. (2014) — EBC-46 anti-tumour mechanism View source ↗
- De Ridder et al. (2021) — Tigilanol tiglate veterinary trial data View source ↗
- ClinicalTrials.gov — Active tigilanol tiglate trials View source ↗
- FDA — Orphan Drug Designation programme View source ↗
